ArticleBMC women's health2022
Analysis of the disease burden trend of malignant tumors of the female reproductive system in China from 2006 to 2020.
Article in BMC women's health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The role of physical activity and exercise in gynecologic cancer care: protocol for an umbrella review.Systematic reviews · 2025Pooled it
- Effect of different interventions on the treatment of high-risk human papillomavirus infection: a systematic review and network meta-analysis.Frontiers in medicine · 2024Pooled it
- Endometrial cancer mortality and its trends in China from 2004-2021.BMC cancer · 2026Article
- Direct economic burden of 0.9 million hospitalized cancer patients in Shenzhen, China, 2016-2022.BMC health services research · 2026Article
- Anesthesia management for a giant ovarian tumor complicated with heart failure: a case report.BMC anesthesiology · 2026Article
- Article
- Protective effect of ammonium trichloride tellurate (AS101) on ovarian injury induced by chemotherapy drug doxorubicin in rats.Journal of ovarian research · 2025Article
- The Burden and Trends of Gynecological Cancers in Asia from 1980 to 2021, with Projections to 2050: A Systematic Analysis for the Global Burden of Disease Study 2021.Current oncology (Toronto, Ont.) · 2025Article
- Article
- The influence of menopause age on gynecologic cancer risk: a comprehensive analysis using NHANES data.Frontiers in oncology · 2025Article
- High-grade serous cancer of left fallopian tube with right inguinal lymph node enlargement: a case report.Frontiers in oncology · 2025Article
- Global burden of ovarian cancer attributable to high body mass index among women of childbearing age from 1990 to 2021 and projections to 2050: a systematic analysis for the global burden of disease study 2021.Frontiers in oncology · 2025Article
- Burden of uterine cancer in China from 1990 to 2021 and 15-year projection: a systematic analysis and comparison with global levels.Reproductive health · 2024Article
- Observational
- Therapy Response and Survival among Patients with Gynecologic Tumors Treated with Transarterial Chemoperfusion and Transarterial Chemoembolization.Medicina (Kaunas, Lithuania) · 2024Article
- A retrospective study on the efficacy and safety of Envafolimab, a PD-L1 inhibitor, in the treatment of advanced malignant solid tumors.Frontiers in pharmacology · 2024Article
- Gender role conflicts experienced by Indonesian women with gynecological cancer: A phenomenological study.Belitung nursing journal · 2024Article
- Temporal trends and projections of gynecological cancers in China, 2007-2030.BMC women's health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMalignant tumors of reproductive system seriously threaten women's life and health. We analyzed the changes in mortality and disease burden of cervical cancer, uterine cancer and ovarian cancer in China from 2006 to 2020 to provide a basis for formulating scientific prevention and control measures.
methodsAnnual death data for cervical cancer, uterine cancer and ovarian cancer were collected from the Chinese Cause of Death Surveillance. The crude mortality rate (CMR), age-standardized mortality rate (ASMR), annual percentage change (APC), and average APC (AAPC) were applied to analyze the trend of mortality. Loss of life expectancy (LLE) and years of life lost (YLL) were used to assess disease burden.
resultsFrom 2006 to 2020, there was no significant change in the total ASMR and standardized YLL rates of malignant tumors of the reproductive system, leading to an average LLE of 0.18 years. The YLL rate was the highest in the 55-59 age group. The mortality rate and disease burden of the three types of cancer have changed from uterine cancer higher than cervical cancer and ovarian cancer in 2006 to cervical cancer higher than ovarian cancer and uterine cancer in 2020. The ASMR and standardized YLL rate of uterine cancer showed a downward trend, and AAPC was - 5.21% (- 9.31% ~ - 0.91%) and - 6.07% (- 9.45% ~ - 2.58%), respectively. The mortality rates of cervical cancer and ovarian cancer remain high.
conclusionThe mortality and disease burden of malignant tumors of the female reproductive system in China are still at a high level. It is necessary to improve screening and prevention strategies as soon as possible, improve the techniques of diagnosis and treatment, and take adequate measures to protect women's life and health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.